期刊文献+

2-氨基甲基-放线菌素D抑制肿瘤细胞增殖的特征

The characteristics of mAct D in inhibiting the proliferation of cancer cells
原文传递
导出
摘要 目的:研究2-氨基甲基-放线菌素D(2-aminomethyl-actinomycin D,mAct D)在对肿瘤细胞和正常细胞的增殖抑制活性及光、热稳定性几方面的特点,为mAct D的进一步开发利用提供理论依据。方法:采用Alamar blue法研究mAct D对体外培养的肿瘤细胞和正常的肝细胞增殖活性的影响;分别进行不同温度的热处理及不同时间的光照处理后检测mActD对肿瘤细胞增殖的影响,从而推测它们的光热稳定性;以上研究结果均以放线菌素D(actinomycin D,Act D)做对照。结果:与Act D相比,mAct D对各肿瘤细胞具有更高的增殖抑制活性,而对正常肝细胞HL7702和人胚肾细胞293T具有更低的抑制活性;两种化合物经过不同温度水浴和不同时间光照处理后,两者的抗肿瘤活性都有所降低,但是mAct D对肿瘤细胞的增殖抑制活性降低较平缓,显示出更高的光、热稳定性。结论:mAct D较Act D相比具有更多的优点,具有成为抗肿瘤新药的潜在价值。 OBJECTIVE To investigate the characteristics of 2-aminomethyl actinomycin D in the inhibiting activity of cancer cells, normal cells and optothermal stability, and to provide theoretical basis for the further exploitation of reAct D. METHODS The inhibiting activity of mAct D was detected by Alamar blue method. To detect the optothermal stability, Act D and mActD were treated with different temperature and light for different time, and then their inhibited proliferation activities in HepG2 cells were detected. RFNULTS Compared with Act D, reAct D showed higher inhibiting activity in cancer cells and lower in HL7702 and 293T cells. The antitumor activities of Act D and reAct D after light, heat treatment were both reduced, but compared with Act D, the activity of mAct D reduced slower. It was suggested that mAct D showed higher optothermal stability. CONCLUSION matt D showed more advantages than Act D, which suggested that mAct D was a potential new anticancer drug.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2014年第14期1160-1164,共5页 Chinese Journal of Hospital Pharmacy
基金 江苏师范大学博士学位教师科研支持项目(编号:10XLR25) 江苏师范大学自然科学研究基金(编号:10XLA20) 江苏省高校自然科学基金项目(编号:11KJB310011)
关键词 2-氨基甲基-放线菌素D 增殖抑制活性 光热稳定性 2-aminomethyl-actinomycin D inhibited proliferation activity optothermal stability
  • 相关文献

参考文献9

  • 1Osborne, RJ, Filiaci, V, Schink, JC, etal. Phase llI trial of weekly methotrexate or pulsed dactinomycin for low risk ges- tational trophoblastic neoplasia: a gynecologic oncology group study[J]. J Clin Oncol, 2011, 29(7): 825-831.
  • 2Sawicki, SG, Godman, GC. On the differential cytotoxicity of actinomycin D[J]. J CelI Biol, 1971, 51)(3): 746-761.
  • 3Mart n-Ldzaro JF, Palanca D, Garcia-liguez JP, etal. Hepa topathy- thrombocytopenia syndrome after actinomycin-d ther apy: treatment with defibrotide[J]. Pediatr Hematol Oncol, 2013, 30 (1):25-27.
  • 4Koba M. Modifications of aetinomycin D structure as example of actinomycins structure-activity relationship[J]. Postepy Hig Med dosw (on line), 2005, 59:276 -282.
  • 5CHEN Y, IdU J, YUAN B, et al. Methylated actinomycin D, a novel actinomycin D analog induces apoptosis in HepG2 ceils through fas- and mitoehondria-mediated pathways[J]. Mol Carcinog, 2013,52(12) : 983-996.
  • 6赵树纬,高怡生.肿瘤的化学治疗ⅩⅣ与放线菌素有关的化合物-2-氨基-吩嗯嗪酮-(3)-衍生物的合成[J].化学学报,1962,4:212.
  • 7Zhang, BZ, Wang KR, Yan, JX, et al. In vitro and in vivo antitumor effects of novel actinomycin D analogs with amino acid substituted in the cyclic depsipeptides [J]. Peptides, 2010, 31(4): 568-573.
  • 8Peng, Y, Song, Y, Feng, L, et al. 7-Amino actinomycin D bound to single-stranded hairpin DNA enhanced by loop se quence-dependent luminescent Eu(3 + ) and Tb(3 + ) binding [J]. J Inorg Biochem, 2009, 103(12) : 1675-1679.
  • 9关晶,高立.3种抗肿瘤抗生素对体外培养淋巴细胞染色体的致畸研究[J].现代预防医学,2011,38(6):1093-1095. 被引量:3

二级参考文献4

  • 1Maluf SW, Erdtmann B. Follow-up study of the genetic damage in lymphocytes of pharmacists and nurses handling antineoplastic drugs evaluated by cytokinesis-block micronuclei analysis and single cell gel electrophoresis assay [J]. Mutat Res, 2000, 471: 21-27.
  • 2Shiraishi T, Yoshida T, Nakata S, et al. Tunicamycin enhancestumornecrosis factor related apop tosis inducing ligand induced apop tosis in human prostate cancer cells [J]. CancerRes, 2005, 65 (14) : 6364-6370.
  • 3孙欣,潘绍山.开展心理咨询 关心护士心理健康[J].解放军护理杂志,2002,19(4):55-55. 被引量:65
  • 4徐世杰,王建新,杨东平.职业性接触抗癌药物的护士染色体损伤调查[J].中华预防医学杂志,2003,37(2):119-120. 被引量:13

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部